Cart

Using Revere's proprietary drug database which tracks the pipeline of every U.S. traded Biotech/Pharmaceutical company, Analysts at Revere are able to continuously monitor the regulatory status of all drug candidates; the result of this unmatched tracking capability is the Revere FDA Approval Decision Report, which provides one of the most comprehensive and accurate event calendars for PDUFA dates (Prescription Drug User Fee Act)-expected FDA approval dates for NDA/BLA filed drugs. In particular, this report identifies Biotech/Pharmaceutical companies with expected FDA approvals in the next 3 months and reviews all FDA approval decisions in the current month. Furthermore, the report also analyzes each drug candidate's likelihood of approval and competitive landscape using 3 criteria derived from Revere's patented classification system: (1) Utilization of a mechanism of action previously approved by the FDA, (2) Facing two or fewer alternative drugs with the same mechanism of action for the same indication, and (3) would be the first or second FDA approved drug for the company. Original, unbiased, insightful and actionable, the Revere FDA Approval Decision Report is an indispensable tool for successful Biotech/Pharmaceutical investing.